Early Morning Insight: Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Zogenix

Thu Jun 20, 2013 10:48am EDT

* Reuters is not responsible for the content in this press release.

Early Morning Insight: Pfizer, Merck & Co., Johnson & Johnson, AbbVie, and Zogenix

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, June 20, 2013 /PRNewswire/ --

Major drug manufacturers in the U.S., as well as globally, face significant challenges as they adapt to changing market dynamics. Perhaps the biggest challenge for major pharma companies is the "patent cliff", which refers to expiration of patents on several blockbuster drugs. The patent cliff has led to increasing competition from generic drug companies. It has forced major drug manufacturers to boost their research & development efforts, and enter into licensing deals. On Wednesday, June 19, 2013, shares in major drug manufacturers ended mostly lower, tracking losses in the broader market which tumbled following the release of Federal Reserve's monetary policy statement. The major movers in the sector included Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Johnson & Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABV), and Zogenix Inc. (NASDAQ: ZGNX). All these companies are tracked by AAAResearchReports.com. Download free technical analysis and charting reports on PFE, MRK, JNJ, ABBV, and ZGNX now at


Shares in Pfizer Inc. fell sharply on Wednesday, tracking losses in the broader market. The company's shares hit an intraday low of $28.90 before finishing the day 1.02% lower at $29.10. A total of 121.04 million shares were traded which is well above the daily average volume of 60.65 million. Pfizer's shares slipped below their 50-day moving average as a result of yesterday's pullback. Download free research on PFE today by registering at:


Merck & Co. Inc.'s stock ended slightly lower yesterday, closing at $47.58, down 0.36% from its previous closing price. The company's shares traded between $47.45 and $48.17 and a total of 18.00 million shares were traded which is below the daily average volume of 22.98 million. Merck & Co.'s shares have fallen by 0.77% so far this week. Besides, the stock is trading below its 50-day and 200-day moving averages.


Shares in Johnson & Johnson moved lower on Wednesday, reversing all of its gains for the week. The company's shares traded between $84.80 and $86.50 before closing the day at $84.86, down 1.74%. A total of 8.29 million shares were traded which is below the daily average volume of 9.64 million. Johnson & Johnson's shares are now down 0.06% for this week. The stock is trading below its 50-day moving average. Sign up and read the complimentary report on JNJ at:


AbbVie Inc.'s stock was one of the worst performers in the healthcare sector yesterday. The company's shares ended the day 1.15% lower at $43.04 after trading between $43.01 and $43.83. A total of 3.66 million shares were traded which is below the daily average volume of 5.01 million. AbbVie's shares are currently trading below their 50-day moving average. In the last three months, the stock has gained 12.20%, thus outperforming the S&P 500. The free report on ABBV can be downloaded by signing up now at:


Shares in Zogenix Inc. rallied on Wednesday, extending their gains from previous trading sessions. The company's shares hit an intraday high of $1.57 before ending the day 4.00% higher at $1.56. A total of 430,026 shares were traded which is below the daily average volume of 550,452. Zogenix's shares have risen by over 11.40% in the last three trading sessions. The stock is trading above its 50-day and 200-day moving averages. Free report on ZGNX can be accessed by registering at




  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.